Somaxon In Commercial Availability

San Diego-based pharmaceuticals firm Somaxon Pharmaceuticals reports this morning that it is now in commercial availability of its Silenor compound in the United States. The firm said it has now implemented wholesale and retail stocking of the compound, which is targeted at the treatment of insomnia. The product's NDA was approved in March of this year. Somaxon has a deal with Proctor & Gamble to promote the product to physicians and pharmacies. The firm is publicly held.